Publication: 2021-09-29NUMAC: 2021033289Federal Public Service Financial administration for policy expertise and support. - Regulation service. - Agreement in mutual consultation between the competent authorities of Luxembourg and Belgium to extend the agreement mutual consultation of 19 May 2020 with regard to the situation of the frontier workers in the context of the fight against the distribution of COVID-19, as extended by the agreements of 19 June 2020.24 August 2020, 7 December 2020, 12 March 2021 and 11 June 20211. Introduction to 19mei 2020 Luxembourg and Belgium concluded an agreement in mutual consultation based on Article 25, paragraph of the agreement between the Kingdom of Belgium and the Grand Duchy of Luxembourg to prevent the prevention of vandublation and regulation of some other matters regarding income and power taxes, and the relevant final protocol, signed on 19.09.1970, as amended by DeAvenanten from 11.12.2002 and 16.07.2009 (hereinafter the "Agreement"). Agreed was published in the Belgian Official Gazette of 29 May 2020, edition 1, bl. 38448.2. Extension the agreement provides that it can be extended from 1 July 2020 until the end of each month if both -authorized authorities agree in writing at least one week before the start of the month. The agreement provides that it can be terminated unilaterally by each competent authority by giving knowledge of this to the other competent authority. This notification must be done at the latest one week before the start of the relevant calendar month. In that case, the agreement will be applicable from the 1st day of the relevant calendar month. On 19 June 2020, the competent authorities of Luxembourg and Belgium have concluded a first agreement that extends the agreement until 31 August 2020. On 24 August 2020, the competent authorities have from Luxembourg and Belgium a second agreement concluded that the agreement extends to December 31, 2020. On December 7, 2020, Debijte Autoegen van Luxembourg and Belgium have concluded a third agreement that extends the agreement to 31 March 2021. On March 12, 2021, the competent authorities of Luxembourg and Belgium concluded that the agreement extends to June 30, 2021. On 11 June 2021, Debijte Autoeggenden van Luxembourg and Belgium have concluded a fifth agreement that extends the agreement to 30 September 2021. In this context, the competent authorities of Luxembourg and Belgium apply to application of the agreement to extend a sixth time until December 31, 2021.3. Announcement deputy extension agreement will be published in the Belgian Official Gazette. Achieved by the undertaked competent authorities on 23 September 2021: for the competent authority of Belgiump.de Vosadvise-General FPS Finance, Belgium for the competent authority of Luxembourg.tousing director of the Taxes, TaxesPublication: 2021-10-04numac: 2021033298federal Agency for Medicines and Health Products28 September 2021.-Decision containing the import and use of the drug Bamlanivimab and Etesevimab for the treatment of COVID-19DE Minister of Health, Geretop the law of 25 March 1964 on the medicines, Article 6quater, § 1, first paragraph, 5 °); having regard to the Royal Decree of 14 December 2006 on medicines for human and veterinary use, Article 110, third paragraph; in view of the advice of the Finance Inspector, given on September 2021; Having regard to the laws on the Council of State, coordinated on January 12, 1973, Article 3, § 1; in view of the urgent necessity; whereas the current premises of COVID-19, a disease caused by the SARS-COV- 2 virus, in Belgium and Derest of the world; whereas the pathogenic and contagious nature of the SARS-COV-2 virus, are different variants who circulate in Europe (see: https://www.ecdc.europa.eu/en/covid-19/Varianhants group) and the significant impact on the transferability, severity and/or immunity that probably have an influence on epidemiological situation in the EU/EEA and on the serious threat that this pays for public health; predominantly the winter period announcing itself, favorable for a peak of respiratory disorders that are common in winter; The dominance of the infectious Delta variant, which entails a greater risk of transfer and hospitalization; Considering the various epidemiological models that have been proposed to the government that announce a possible new peak of the pandemiexes consequences of SARS-COV2 in the period October/November ; Considering the full vaccination rate in certain zones in Belgium is only about 50 % (on 23/09/2021), which is not yet a guarantee i s for optimum protection for certain population groups; whereas the treatments that have been licensed to treat COVID-19 are still limited; Only fevering dexamethasone are indicated in patients older than 12 years with pneumonia who are oxygen therapy needed; whereas the positive interim results of the clinical study with the medicine bamlanivimab and ethesevimab, two monoclonal antibodies that have been demonstrated with Devirale with Devirale -COV-2 Reduce (see https://www.ema.europa.eu/en/documents/referral/eli-lilly-company-company-antibody-body-bamlanivimab/etesevimab-covid19-article-53-procedure-assessment -Treport_en.pdf); Considering the scientific advice of 16/03/2021 of the Medicines Committee for Human Use (Committee for Medicinal Products for Human Use - CHMP), lodged at the European Medicines Office (EMA), in which this committee comes to the decision that, based on available preliminary data from the current clinical study that this monoclonal antibodies combination can be used for the Treatment of patients with COVID-19 who do not need oxygen therapy and who develop risk running a serious form of COVID-19; ChMP (see https://www.ema.europa.eu/en/documents/referral/eli-lilly-company-company-antibody-Antibody-bamlanivimab/eteseevimab-covid19-article-53-procedure-Conditionsuse-condition -Distribution patient-targeted_enpdf) -19 in Belgium ", prepared by the Scientific Committee founded within Sciensano, as one of the treatment options for patients with moderate COVID-19, who belong to a risk category as a result of the presence of other pathologies at the time of infection with the SARS-COV-2 virus; predominant the common advice on access to antibodies against SARS-COV-2 for the early treatment of patients with immune deficiencies of the Royal Academy of Medicine of Belgium (KAGB) and Académie Royale de Médecine de Belgique (Armb) of 30 April 2021; that the Belgianestate at the end of September 2021 on a strategic stock of mon Oklonal antibodies should have that should be delivered as soon as possible according to the needs of the hospitals, in order to suffer patients who suffer from SARS-COV-2 and to develop a serious form of COVID-19, treat the import, decides, decide, The purchase, episode and administration of the combination of monoclonal antibodies to allow bamlanivimab and eteseimab to the treatment of COVID-19 drilled by the SARS-COV-2 virus, under the following conditions: 1 ° the drug combination Bamlanivimab and Etesevimab can only be prescribed by a doctor, connected to hospital, as referred to in Article 2 of the coordinated law of 10 July 2008 at the hospitals and other care institutions, and this after a prior advice, of a multidisciplinary expert panel, consisting of doctors associated with a university hospital, as referred to in Article 4 of the coordinated law of 10 July 2008 on the hospitals and other care institutions. This panel of experts consists at least an infectiologist and immunologist. When prescribing as well as formulating the advice by the expert panel, the recommendations are included in the denational treatment guideline "Interim Clinical Guidance for Adults with Suspended or Confirmed Covid-19 in Belgium"; 2 ° Only a hospital pharmacy, as referred to in Article 1, 1 °, of the Royal Decree of 30 September 2020 containing the preparation and delivery of medicines and using the distribution of medical devices within care institutions, can, after submitting one -medical prescription, the combination of medicines can order Bamlanivimab and Etesimabab from the minister designated wholesaler which manages strategic stock of venematic agents on behalf of the Belgian state; 3 ° The aforementioned hospital pharmacy fills in the form of this decision with every import, every purchase or order of the drugs bamlanivimab andetesimab; These forms are stored in a unique register that is kept available of the Fagg; 4 ° the Medicines Bamlanivimab and Eteivimab are administered under Medischtzurgeicht from a doctor associated with a hospital, as referred to in Article 2 of the Coordinated Act of 10 July 2008 at the hospitals and other care institutions; 5 ° the hospitals sets monthly follow -up reports of the treatments administered to patients treated with the drugs bamlanivimab and etheimabab. These reports only contain anonymized, aggregate data, and contain at least: the suspected unwanted side effects that were determined, the mortality figures in 29 days after administration and the recording at intensive care within 29 days after administration. These reports are transferred monthly to the FAGG.6 ° In the event that a permit for the trade, as referred to in Article 3, first paragraph, of Regulation (EC) No 726/2004 of the European Parlements, the Council of 31 March 2004 adopted of Community procedures for granting permits and the supervision of medicines for human and veterinary use and the establishment of a European Medicines Office has been granted for the medicine in question, the packaging of the pierced drugs are bamlanivimab and etesimababababababababababababababababababababababababababababababababit are still available in the strategic stock of the Belgian State, divided and uses the conditions of this decision. This decision applies immediately. The decision is valid until 1 June 2022. However, it will be shown as soon as Bamlanivimab and Eteseimab is a permit for the marketing of COVID-19.Brussel, 28 September for the combination of Bamlanivimab and Eteseimab 2021The Minister of Health, Fr.vandenbroucke for the consultation of the table, see Visual to be added to our decision of 28 September 2021.Deminister of Health, Fr.VandenbrouckePublication: 2021-10-04numac: 2021033299federal Agency for Medicines and Health Products28 September 2021.-Decree on the permission for the import and use of the drug Sotrovimab for the treatment of COVID-19De Minister of Health, Given the law of March 25, 1964 on the Medicines, Article 6quater, § 1, first paragraph, 5 °); in view of the Royal Decree of 14 December 2006 on medicines for human and veterinary use, Article 110, third paragraph; Having regard to the advice of the Finance Inspector, given on September 2021; In view of the laws on the Council of State, coordinated on January 12, 1973, Article 3, § 1; In view of the urgent necessity; whereas the current premises of COVID-19, a disease caused by the SARS-COV-2 virus , in Belgium and Derest of the world; whom the pathogenic and contagious nature of the SARS-COV-2 virus, are different variants that have CI in Europe rculate (see: https://www.ecdc.europa.eu/en/covid-19/varianhantsgrace) and the significant impact on the transferability, severity and/or immunity that probably have an influence on the epidemiological situation in the EU/EEA and on the serious threat that this pose for public health, the contagious Delta variant, which entails a greater risk of transfer and hospitalization; Considering the different epidemiological models that have been proposed to the government that announce a possible new peak of the pandemiexes of SARS-COV2 in the period October/November; full vaccination rate in certain zones in Belgium is only approximately 50 % (on 23/09/2021), which is not yet a guarantee for optics ale protection for certain population groups; Only Vlakuryen Dexamethasone are indicated in patients over 12 years of age with pneumonia who have oxygen therapy need; whereas the positive interim results of the clinical study with the Sotrovimab, a monoclonal antibody that has a fall in an interim analysis of the number of hospital and death of the number of hospital recordings demonstrate (see https://www.ema.europa.eu/en/news/ema-issues-adviezen- use-sotrovimab-vir-7831-treatment covid-19); Considering the scientific advice of 21/05/2021 of the Committee for Medicines for Human Use (Committee for Medicinal Products For Human Use - CHMP), established at the European Medicines Office (EMA), in which this committee comes to the decision on the basis of available preliminary Data from the current clinical study Datdze Monoclonal AntiLichame can be used for the treatment of patients with COVID-19 who do not require any oxygen therapy and who run the risk of developing a serious form of COVID-19; as well as the supervision of safety, included as an appendix to the same advice from the CHMP (see https://www.ema.europa.eu/en/documents/referral/sotrovimab-also-known-vir-7831-gsk4182136-covid19--9- article-53 procedure-conditions-use-conditions_enpdf) -19 in Belgium ", prepared by the Scientific Committee founded within Sciensano, as one of the treatment options for patients with moderate COVID-19, who belong to a risk category as a result of the presence of other pathologies at the time of infection with the SARS-COV-2 virus; predominant the common advice on access to antibodies against SARS-COV-2 for the early treatment of patients with immune deficiencies of the Royal Academy of Medicine of Belgium (KAGB) and Académie Royale de Médecine de Belgique (Armb) of 30 April 2021; that the Belgianestate at the end of September 2021 on a strategic stock of mon Oklonal antibodies should have that should be delivered as soon as possible according to the needs of the hospitals, in order to suffer patients who suffer from SARS-COV-2 and to develop a serious form of COVID-19, treat the import, decides, decide, The purchase, delivery and administration of sotrovimabe to be treated for the treatment of COVID-19 caused by the SARS-COV-2 virus, under the following conditions: 1 ° The sotrovimab drug can only be prescribed by a doctor connected to a hospital, connected to a hospital, As referred to in Article 2 of the Coordinated Act of 10 July2008 at the hospitals and other care institutions, and this after a prior advice, of one -multi -disciplinary expert panel, consisting of doctors associated with a University Hospital, as referred to in Article 4 of the Coordinated Act of 10 July 2008 at the hospitals and other care institutions. This panel of experts exists least Ens from an infectiologist and immunologist. When prescribing as well as formulating the advice by the expert panel, the recommendations were taken into account in the National Treatment Directive "Interim Clinical Guidance for Adults with Suspedor Confirmed COVID-19 in Belgium"; 2 ° Only a hospital pharmacy, as referred to in Article1, 1 ° , of the Royal Decree of 30 September 2020 on the preparation and delivery of medicines the use and distribution of medical devices within care institutions, can, after submitting a medical prescription, order the sotrovimab medicine from the wholesaler who is commissioned by the minister who on behalf of the Belgian state manages strategic stock of medicines; 3 ° The aforementioned hospital pharmacy fills in the form attached to this decision with every entry, each application or order of the sotrovimab drug; These forms are stored in a unique register that is kept available to the FAGG; 4 ° The drug Sotrovimabab is served by a doctor's medical supervision associated with a hospital, as referred to in Article2 of the Coordinated Act of 10 July 2008 on the hospitals and others Care institutions; 5 ° Hospitals prepare monthly follow -up reports of the treatments administered to patient treated with the sotrovimab drug. These reports only contain anonymized, aggregate data, and contain at least: the suspected unwanted side effects that were determined, the mortality figures in 29 days after administration and the recording at intensive care within 29 days after administration. These reports are transferred monthly to the FAGG.6 ° In the event that a permit for the trade, as referred to in Article 3, first paragraph, of Regulation (EC) No 726/2004 of the European Parlements, the Council of 31 March 2004 adopted Community procedures for granting permits and the supervision of medicines for human and veterinary use and the establishment of a European medicine agency has been granted for the medicine in question, the packaging of the no-granted drug Sotrovimab that is still decisivable at the time of granting a stated permit are divided and used in the strategic stock of the Belgian State, and used conditions of this decision. This decision applies immediately. The decision is valid until 1 June 2022.brussel, 28 September 2021. The Minister of Health, Fr. Vandenbroucke for the consultation of the table, see image seen to be added to our decision of 28 September 2021. The Minister of Health, Fr. Vandenbroucke